Anixa Biosciences, Inc. (NASDAQ:ANIX) Sees Large Increase in Short Interest

Anixa Biosciences, Inc. (NASDAQ:ANIX) was the recipient of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 403,100 shares, a growth of 13.7% from the January 15th total of 354,500 shares. Based on an average daily volume of 121,000 shares, the short-interest ratio is presently 3.3 days. Approximately 1.3% of the shares of the stock are sold short.

Anixa Biosciences Price Performance

Anixa Biosciences stock traded down $0.01 during trading on Friday, reaching $3.14. The company had a trading volume of 67,120 shares, compared to its average volume of 132,831. Anixa Biosciences has a 12-month low of $2.07 and a 12-month high of $4.35. The stock’s 50 day moving average price is $2.70 and its two-hundred day moving average price is $3.05.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. Sell-side analysts predict that Anixa Biosciences will post -0.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a research report on Tuesday, November 19th. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a report on Wednesday, January 22nd.

Insider Activity at Anixa Biosciences

In other Anixa Biosciences news, CEO Amit Kumar bought 43,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was bought at an average price of $2.23 per share, for a total transaction of $95,890.00. Following the completion of the transaction, the chief executive officer now owns 559,925 shares in the company, valued at approximately $1,248,632.75. The trade was a 8.32 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lewis H. Titterton, Jr. bought 10,000 shares of the business’s stock in a transaction on Friday, January 17th. The shares were acquired at an average price of $2.57 per share, with a total value of $25,700.00. Following the transaction, the director now owns 922,334 shares of the company’s stock, valued at $2,370,398.38. The trade was a 1.10 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased 75,289 shares of company stock worth $177,021 over the last 90 days. Company insiders own 22.60% of the company’s stock.

Institutional Investors Weigh In On Anixa Biosciences

Institutional investors have recently bought and sold shares of the stock. International Assets Investment Management LLC grew its stake in Anixa Biosciences by 170.0% during the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after buying an additional 23,800 shares during the period. Tyler Stone Wealth Management grew its stake in Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after buying an additional 21,008 shares during the period. Virtu Financial LLC purchased a new stake in Anixa Biosciences during the third quarter worth approximately $34,000. Westside Investment Management Inc. grew its stake in Anixa Biosciences by 151.8% during the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after buying an additional 21,100 shares during the period. Finally, Prosperity Wealth Management Inc. purchased a new stake in Anixa Biosciences during the fourth quarter worth approximately $54,000. 29.13% of the stock is currently owned by hedge funds and other institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.